Imaging in clinical oncology trials provides a wealth of information that contributes to the drug development process, especially in early phase studies. This paper focuses on kinetic modeling in DCE-MRI, where the subjects were imaged before and after two cycles of chemotherapy, demonstrating the clinical potential of this method to longitudinal oncology studies.
The goal of model construction and estimation presented here is to quantify the effect of drug treatment on disease -in this case breast cancer -through quantitative summaries of tumor microvasculature using DCE-MRI. The model framework we have adopted provides a unified treatment of imaging information at the study level through simultaneous estimation of parameters at the voxel, patient and treatment level, allowing a thorough interrogation of the results.
Bayesian Hierarchical Model
Bayesian methods rely on the specification of prior distributions p(θ) that express our information about the unknown parameters θ before any measurements are obtained; i.e., our model assumptions. To assess the model parameters after observing the data, the posterior distribution p(θ | Y) can be computed, where θ is the vector of all unknown parameters and Y is the vector of observations. The posterior distribution of the parameter vector θ is obtained by applying Bayes' theorem
where ℓ(Y | θ) denotes the likelihood function of Y and p(θ) the product of all a priori probability distribution functions. One can think of the posterior as an update to the prior distribution, our beliefs, on θ after measuring a process -producing a mixture of previous knowledge and experimental data.
Bayesian methods are inherently iterative, since the posterior distribution can become our new prior distribution and, be combined with new measurements of the data generating process at a later date, to produce an updated posterior distribution.
The following sections introduce the key components in the Bayesian hierarchical model: the data model, the parameter model and the prior parameters. Each stage of the model development has been tailored to the analysis of a longitudinal cancer treatment study with two time points. Figure 1 provides a schematic overview of the proposed Bayesian Hierarchical Model (BHM). The three model stages are the rows and the columns represent the "resolution" of the parameters. For example, K trans is decomposed into global (study-wide), subject and voxel effects through the BHM where as v p is simply estimated for each voxel without further decomposition. The measurement error term is independent of the specific parameter model and involves both prior and hyperprior distributions. A standard compartmental model is used to describe the concentration time curves observed at each voxel. A generalized additive model is proposed to decompose the kinetic parameters into factors that are relevant to the design of the longitudinal study. Finally, the prior distributions, including necessary hyperparameters, are specified on all factors of the parameter model. These prior distributions are flat in most cases, reflecting a lack of knowledge concerning the parameter, but also incorporate biological knowledge, such as a transfer rate must be non-negative, or statistical knowledge, for example a variance must be non-negative.
Data Model
A hierarchical Bayesian framework is used to model the contrast agent concentration time curve (CTC) of all voxels (17) .
T denote the CTC associated with a single voxel observed at T time points determined by the image acquisition protocol. The CTC is assumed to follow a standard compartment model (16) [3 ] where ⊗ denotes the convolution operator, K trans represents the transfer rate from plasma to extracellular extravascular space (EES) per minute, k ep the rate constant between EES and blood plasma per minute and v p the vascular space fraction. The choice of model for the CTC depends on the scientific goals of the study. Replacing Eq. [3] with a more or less complicated model is straightforward in this model-building framework. The observed vector Y may therefore be thought of as noisy observations of the true contrast agent concentration C t (t) given by a draw from a multivariate Normal distribution
where the notation Y ∼ N(µ, σ 2 ) means that the random variable Y is drawn from the Normal distribution with parameters µ and σ 2 .
We assume a common arterial input function (AIF), taken from the literature for all patients in the study, and we follow the work of Tofts and Kermode (12) by using a bi-exponential function
where a 1 = 24.0 kg/l, a 2 = 6.20 kg/l, m 1 = 3.00 min −1 and m 2 = 0.016 min −1 are inspired by the work of Fritz-Hansen et al. (15) .
A Bayesian implementation of the compartmental model above was proposed in Schmid et al. (18) .
Since the Bayesian model framework does not depend on any optimization procedure, it will produce valid parameter estimates when estimation via nonlinear regression fails to converge. Samples from the posterior distribution are built up during the model fitting procedure for each parameter. Hence, the posterior distribution may be used to obtain additional information on the accuracy and precision of the estimates. For example, the standard error of the posterior is the estimation error. Statistics of interest may be derived from the posterior distribution (e.g., mean, median, quantiles, etc. ) so that not only point estimates but also confidence intervals are readily available.
Parameter Model
The pharmacokinetic (PK) parameters from the data model are estimated at every tumor voxel across all subjects and scans. We assume a priori that the distribution of the random variables K trans and k ep in the tumor are patient-specific and are changed by treatment in a similar way. Therefore a generalized additive model is used where the log-transformed kinetic parameters ln(K trans ) and ln(k ep ) are expressed as a linear combination of fixed-and random-effects associated with identifiable factors in the study.
In addition to mathematical convenience, the log transform is also appealing in this context because individual terms in the additive model may be interpreted as percentage change from baseline. We assume that the distribution of the vascular fraction v p will not be changed by the treatment, however single v p values will be changed. Let i = 1, . . . , I denote the scans acquired and let j = 1, . . . , J denote the patients, so that n ij denotes the number of tumor voxels for patient j at scan i, measured at T time points. The transfer rate constants in Eq. [3] are assumed to be non-negative and estimated in log-transformed space. That is, let
The factor of interest when measuring a change in the kinetic parameters is the treatment effect, or the difference between scan i = 1 and scan i = 2 when only pre-and post-treatment images are acquired.
We acknowledge the fact that substantial variability exists across patients in the study and between the voxels in each region of interest (ROI) that describes the enhancing region in the acquisition. Hence, the model for ln(K trans ) is given by
where
0 otherwise.
The parameter α 1 is the value of ln(K trans ) associated with the baseline scan and β 1 is the treatment effect (since it is only associated with the post-treatment acquisition). These parameters are regarded as fixed effects (the global column of Figure 1 ), and thus do not vary between patients in the study.
In the Bayesian framework, a marginal posterior distribution will be available for each parameter. The parameter γ j1 is the effect of patient j on ln(K trans ) and δ j1 is the interaction between patient j and treatment. These parameters are random effects since each patient is assumed to be drawn from a larger population of patients suffering from this condition (the subject column of Figure 1 ). Finally, the parameter ǫ ijk1 is the random effect of voxel k in scan i of patient j on ln(K trans ). The voxel effect acknowledges the fact that each voxel in the tumor volume is drawn from a distribution that describes the ideal tumor voxel (the voxel column of Figure 1 ). The combination of fixed and random effects in a single model is commonly referred to as a mixed-effects model (6) .
Using matrix notation, we can combine the generalized additive model across both kinetic parameters, ln K trans and ln k ep , such that
The scan-specific covariates in the model are captured in Z i , the fixed effects are in φ l , the patient-specific random effects are in θ jl and the voxel-specific random effects are in ǫ ijkl . The model formulation in Eq. [8] can be adapted in order to incorporate a greater number of scans in a longitudinal study.
Prior Models
In the Bayesian framework prior information with unknown variance is used to model the random effects.
We use vector notation to denote the patient-specific random effects such that
where we have dropped the kinetic parameter subscript to simplify the notation. We draw from multivariate Gaussian distributions to characterize the prior distribution of the unknown variances for the patient-specific random effects, i.e.,
where τ 2 γ and τ 2 δ are vectors of the same length and indexed as γ and δ, respectively. The voxel-specific random-effect vectors are given unique prior distributions by scan, patient and parameter, so that each vector is given by
T and it is drawn from a multivariate Gaussian distribution
where n ij is the number of voxels in the region of interest of scan i of patient j, and τ 2 ǫ;ijl is the unknown variance associated with scan i, patient j and parameter l. Since the variances are unknown parameters, they must have their own prior distributions which are given by
where IG(a, b) denotes the Inverse Gamma distribution (19) , allowing only non-negative values. The inverse Gamma distribution is a conjugate prior for the Normal distribution. For the fixed effects we use flat priors; i.e., the prior distribution does not contain any relevant information, such that
The prior distributions on the coefficients in the generalized additive model are chosen so that as much variance in the data is explained by the fixed effects α and β -as no prior information is used for those parameters. Variability which cannot be explained by the fixed effects will be covered by the random effects γ and δ. For these parameters an additional prior distribution (hyperprior) on the variance of the parameters is defined, which leads to a shrinkage of those effects, that is the parameters are pushed towards zero and therefore do not cover variance explained by the fixed effects. Any additional variance is explained by the voxel effects.
For the vascular space fraction we impose a relatively flat prior
where B(a, b) denotes the Beta distribution (20) , so that the a priori expected value of v p is 0.05.
The Bayesian hierarchical model is complete by specifying a prior distribution for the variance of the observational error in Eq. [4] , with one variance parameter per scan per patient,
3 Materials and Methods
Data acquisition
The first twelve patients from a previously reported breast cancer study are included in the analysis (21; 18). Data were provided by the Paul Strickland Scanner Centre (PSSC) at Mount Vernon Hospital, Northwood, UK. Each patient underwent a DCE-MRI study before and after two cycles of chemotherapy (5-fluorouracil, epirubicin and cyclophosphamide). Six of these patients were identified as pathological responders after receiving six cycles of chemotherapy, the others were non-responders.
For the calculation of T 1 values, we used a two-point measurement with calibration curves as described in (22; 23 256 × 256 voxels and one slice placed in the contra lateral breast as control, which we do not use for our analysis. A total of 40 to 50 acquisitions were acquired, with one acquisition each 11.9 seconds. A dose of D = 0.1 mmol per kg body weight of Gd-DTPA was injected after the fourth scan using a power injector with 4 ml/s with a 20 ml saline flush also at 4 ml/s. The first four scans, before contrast, were used to compute T 10 as the average of the T 1 values of these images. Data from this study were acquired in accordance with the recommendation given by (24) . Informed consent was obtained from all patients.
Regions of interest (ROIs) were drawn manually by an expert radiologist on a scan-by-scan basis using anatomical images and subtraction images from the dynamic data to define tumor voxels in pre and post treatment scans.
Parameter Estimation via MCMC
The joint posterior distribution of all parameters was assessed using Markov chain Monte Carlo (MCMC) (25) . After a initial burn-in phase of 10,000 iterations, another 100,000 iterations were computed. To ensure independent samples only each 100th sample was used, giving us a total of 1000 samples to describe the posterior distribution. The global parameters φ and patient-specific θ j were drawn en bloc in Gaussian Gibbs steps (26) , and hyperparameters were drawn in independent Gamma Gibbs steps;
technical details can be found in Appendix A.1. Metropolis-Hastings steps with random walk proposals were necessary for the voxel-specific random effects and vascular space fraction. The algorithm was tuned to an acceptance rate of 30-50% (27) . Summary statistics were computed from the samples of the posterior distribution to provide point estimates of the parameters. Empirical standard errors, along with sample quantiles, were used to characterize the precision of the parameter estimates.
Results
All parameter estimates are derived from the posterior distribution using Bayes theorem. Hence, a sampling distribution for each parameter value has been built up from which we can produce a point estimate via the median of the sample and also credible intervals (Bayesian confidence intervals) by using the quantiles from their sampling distributions. The density estimates in Figure 3 are unimodal and indicate an overall decrease in K trans after treatment. In order to test for a treatment effect on K trans , specifically a reduction in K trans in the second acquisition compared to the first, we construct the hypothesis
using the treatment effect from the parameter model (Eq. [8] ) and calculate the posterior probability of median reduction in K trans which is very similar to the overall treatment effect. This is definitely not the norm as patient 9 experienced a 100% · |0.4285 − 1| = 57.2% median reduction in K trans and patient 6 experienced a 100% · |1.0817 − 1| = 8.17% median increase in K trans , both were pathological responders. 
Discussions and conclusions
Information is obtained at multiple levels during an imaging study in the clinical trial setting. The The Bayesian hierarchical model presented here was developed to test the hypothesis of a treatment effect for an imaging study while acknowledging known sources of uncertainty; e.g., patients and voxels. This is similar to the approach taken in standard analysis methods for clinical trials where fixed and random effects are identified in the model. The specification of fixed and random effects allows the results from the study to be applicable beyond the specific patient population recruited for this specific study.
A standard analysis was performed on the ROIs and the median K trans values have been summarized in Table 1 . A non-parametric test (a one-sided Wilcoxon signed rank test) was performed to test that the difference between the median values was greater than zero; i.e., the treatment did not reduce K trans across all subjects. The null hypothesis was rejected at a borderline significance level (p = 0.055). Given the small sample size, N 1 = 6 responders and N 2 = 6 non-responders, this is an impressive result and there is obviously a reasonable difference in K trans between the two groups. Figure 6 shows the kernel density estimates of K trans for each ROI, before and after treatment, using a voxel-wise non-linear regression analysis. That is, the compartmental model in Eq. [3] was fit to each voxel independently using the Levenberg-Marquardt optimization procedure. The empirical distributions observed for each patient are extremely similar to those obtained in the BHM. This is to be expected given the relatively flat priors that were imposed on the kinetic parameters (18) .
While the voxel-wise results from the Bayesian and regression methods are very similar, and thus provide a check on the consistency of the Bayesian model fitting procedure, the advantages of the Bayesian hierarchical model are clear through the coefficients from the generalized additive model (Eq. [8] ). The regression analysis can only summarize the study through Table 1 , but the BHM allows one to isolate and interrogate specific effects, at the study or patient or voxel level, through the generalized additive model. Examples of such interrogations have been presented here in Figures 3 and 4 , but the possibilities for such model summaries are only limited by the construction of the parameter model.
Bayesian models rely on a priori beliefs about the model and parameters, expressed as prior distributions. In general, a flat prior provides similar information to a maximum likelihood approach, and hence similar results. However, in the Bayesian hierarchical model proposed here the choice of prior distribution is critical in specifying the model. We used flat priors on the baseline α and on the treatment effect β, and thus the approach is similar to a non-Bayesian or frequentist approach. For the patient specific effects γ and δ we used Gaussian priors with unknown variances; this is also known as shrinkage prior, as it shifts the parameters towards zero. Hence the patient-specific effects only pick up the deviation from baseline and treatment effect. The voxel effect was also given a shrinkage prior with a more informative hyperprior distribution on the variance, hence it only picks up variability after modelling the baseline, treatment and patient-specific effects.
In this paper a generalized additive model was constructed for the kinetic parameters (K trans and k ep ) in a compartmental model. This model incorporated two scanning sessions, and all subjects, to asses the effect of treatment. The modeling framework is easily extended to handle additional covariates or scanning sessions. For example, a dose-ranging study design could be incorporated into the additive model where the treatment effect can be expressed as a function of the dose. Additional scans over time would enable the assessment of temporal dependence on treatment and provide information about the reliability of the data by potentially reducing the amount of uncertainty in the parameter estimates.
Another possible extension of this model would be to include the spatial information of adjacent voxels.
In the current implementation of the Bayesian hierarchical model all voxels from one region of interest (tumor) were treated as spatially independent. Since voxel borders are arbitrary and do not represent physiological boundaries between different tissue types, it is likely that neighboring voxels share similar perfusion characteristics. This fact has been taken advantage of in the context of Bayesian modeling of individual scans from a DCE-MRI study (18) . The inclusion of a neighborhood structure in the modeling process would reduce the uncertainty in estimation and provide more reliable estimates of the kinetic parameters.
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A Appendix

A.1 Full conditional distributions
In each iteration of the MCMC (Markov chain Monte Carlo) algorithm, a random sample of the marginal posterior distribution for all parameters is drawn. This is performed by drawing from the conditional posterior distribution of one or more parameters given all other parameters and the data. Hence, the full conditional distributions must be computed. The full conditional is denoted by θ | ·, where θ is the parameter and · denotes all other parameters and the data. If the full conditional takes the from of a standard distribution, one can sample directly form this distribution; this is known as the Gibbs sampler (25) . If the full conditional is not a standard distribution, then a Metropolis-Hastings sampler must be constructed.
In the proposed Bayesian hierarchical model all full conditionals are from standard distributions due to the use of conjugate prior distributions, except for the voxel effect and
denote the vector of length P = I(J + 1) associated with all parameters in the generalized additive model, except the voxel effect, for a specific kinetic parameter. The full conditional of ξ l is a multivariate Normal distribution given by
w ijp ψ ijkl for p = 1, . . . , P ,
where W is a I(J + 1) × P matrix indicating which covariate should be included in the parameter model (Eq. [8] ) and Λ is a diagonal matrix with elements n ij τ ǫ;ij . The vector ξ l is drawn in one block from a multivariate Normal distribution with an efficient block-sampling algorithm (29) .
The full conditional distribution of the voxel effect ǫ ijkl is a non-standard distribution. For computational reasons it is more convenient to sample from ψ ijkl rather than from ǫ ijkl . where the full conditional distribution of ψ ijkl is given by
[21 ]
Note, Y ijkl is the estimated contrast agent concentration curve given by the estimated model parameters inψ ijkl . Draws from this distribution are obtained using a Metropolis-Hastings step.
The full conditionals of all variance parameters are inverse Gamma distributions, which are given by
Figure Captions At pre-treatment K trans is given by exp(α 1 + γ j1 + ǫ 1jk1 ) for scan 1, patient j and voxel k. At post-treatment K trans is given by exp(α 1 + β 1 + γ 1j + δ 1j + ǫ 12jk ) for scan 2, patient j and voxel k. 
